Briacell Therapeutics Corp Financials
This page shows Briacell Therapeutics Corp (BCTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing-led liquidity supports a research-driven loss profile while operating cash needs remain the central business constraint.
FY2024 paired operating cash flow of-$24.1M with just$0.9M of cash, leaving little balance-sheet cushion. By FY2025, financing supplied$45.4M while operating cash flow deteriorated to-$28.2M , so the subsequent liquidity restoration was financing-led rather than earned by operations.
FY2025 R&D was
Capital intensity is not the main drain: FY2024 capital expenditures were only
Financial Health Signals
Briacell Therapeutics Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Briacell Therapeutics Corp passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass.
Briacell Therapeutics Corp reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Briacell Therapeutics Corp reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Briacell Therapeutics Corp's EBITDA was -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Briacell Therapeutics Corp reported -$26.3M in net income in fiscal year 2025. This represents a decrease of 449.1% from the prior year.
Briacell Therapeutics Corp earned -$62.19 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Briacell Therapeutics Corp held $10.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Briacell Therapeutics Corp's ROE was -151.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Briacell Therapeutics Corp invested $21.3M in research and development in fiscal year 2025. This represents a decrease of 21.7% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BCTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $21.3M-21.7% | $27.2M+77.2% | $15.3M+91.2% | $8.0M+296.9% | $2.0M |
| SG&A Expenses | N/A | $5.9M-3.5% | $6.2M-22.5% | $7.9M+9.2% | $7.3M+46.7% | $5.0M |
| Operating Income | N/A | -$27.2M | N/A | -$23.3M-52.2% | -$15.3M-119.2% | -$7.0M |
| Interest Expense | N/A | $37K | N/A | N/A | $979-98.8% | $79K |
| Income Tax | N/A | N/A | N/A | N/A | $0 | $0 |
| Net Income | N/A | -$26.3M-449.1% | -$4.8M+76.4% | -$20.3M+24.4% | -$26.8M-94.3% | -$13.8M |
| EPS (Diluted) | — | -$62.19 | -$43.68 | -$1.30+24.9% | -$1.73 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Total Assets | $21.6M+268.7% | $5.9M-78.4% | $27.2M-36.2% | $42.6M-26.6% | $58.0M |
| Current Assets | $19.9M+445.4% | $3.7M-86.4% | $26.9M-36.4% | $42.3M-26.7% | $57.8M |
| Cash & Equivalents | $10.5M+1117.3% | $862K-95.9% | $21.3M-48.2% | $41.0M-28.3% | $57.3M |
| Accounts Receivable | N/A | N/A | $19K-21.7% | $24K+91.7% | $13K |
| Total Liabilities | $4.3M-49.6% | $8.6M-72.3% | $30.9M-4.1% | $32.2M+6.2% | $30.4M |
| Current Liabilities | $4.0M-46.7% | $7.5M+314.2% | $1.8M+91.4% | $941K+69.0% | $557K |
| Total Equity | $17.3M+745.6% | -$2.7M+28.9% | -$3.8M-136.6% | $10.3M-62.7% | $27.7M |
| Retained Earnings | -$111.8M-30.8% | -$85.4M-5.9% | -$80.7M-33.6% | -$60.3M-107.1% | -$29.1M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
BCTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$30.8M | -$28.2M-16.8% | -$24.1M-1.6% | -$23.7M-90.2% | -$12.5M-61.1% | -$7.8M |
| Capital Expenditures | N/A | N/A | $457K | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$24.6M | N/A | N/A | N/A |
| Investing Cash Flow | -$16.2M | -$7.6M-1021.4% | -$682K | N/A | N/A | N/A |
| Financing Cash Flow | N/A | $45.4M+928.5% | $4.4M+11.7% | $4.0M+205.7% | -$3.7M-105.8% | $65.0M |
| Share Buybacks | N/A | N/A | N/A | $47K-99.5% | $10.2M | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Return on Equity | -151.8% | N/A | N/A | -259.8%-209.9pp | -49.9% |
| Return on Assets | -121.5%-39.9pp | -81.6%-6.9pp | -74.7%-11.7pp | -63.0%-39.2pp | -23.8% |
| Current Ratio | 5.01+4.5x | 0.49-14.5x | 14.96-30.0x | 45.00-58.8x | 103.81 |
| Debt-to-Equity | 0.25 | N/A | N/A | 3.12+2.0x | 1.10 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Briacell Therapeutics Corp Ranks
Frequently Asked Questions
Is Briacell Therapeutics Corp profitable?
No, Briacell Therapeutics Corp (BCTX) reported a net income of -$26.3M in fiscal year 2025.
What is Briacell Therapeutics Corp's EBITDA?
Briacell Therapeutics Corp (BCTX) had EBITDA of -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Briacell Therapeutics Corp's return on equity (ROE)?
Briacell Therapeutics Corp (BCTX) has a return on equity of -151.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Briacell Therapeutics Corp's operating cash flow?
Briacell Therapeutics Corp (BCTX) recorded an outflow of $28.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Briacell Therapeutics Corp's total assets?
Briacell Therapeutics Corp (BCTX) had $21.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Briacell Therapeutics Corp spend on research and development?
Briacell Therapeutics Corp (BCTX) invested $21.3M in research and development during fiscal year 2025.
What is Briacell Therapeutics Corp's current ratio?
Briacell Therapeutics Corp (BCTX) had a current ratio of 5.01 as of fiscal year 2025, which is generally considered healthy.
What is Briacell Therapeutics Corp's debt-to-equity ratio?
Briacell Therapeutics Corp (BCTX) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Briacell Therapeutics Corp's return on assets (ROA)?
Briacell Therapeutics Corp (BCTX) had a return on assets of -121.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Briacell Therapeutics Corp's cash runway?
Based on fiscal year 2025 data, Briacell Therapeutics Corp (BCTX) had $10.5M in cash against an annual operating cash burn of $28.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Briacell Therapeutics Corp's Piotroski F-Score?
Briacell Therapeutics Corp (BCTX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Briacell Therapeutics Corp's earnings high quality?
Briacell Therapeutics Corp (BCTX) reported a net loss of $26.3M while operations used $28.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Briacell Therapeutics Corp cover its interest payments?
Briacell Therapeutics Corp (BCTX) reported an operating loss of $27.2M against $37K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.